What 23andMe business troubles could mean for users' genetic data
In this photo illustration, a 23andMe logo seen displayed on a smartphone and in the background. The company announced Monday that it would lay off around 40% of its workforce -- about 200 employees -- and close its drug development arm in an attempt to ...
( NewsNation) — Genetic testing company 23andMe has faced a series of struggles this year, culminating in end-of-year mass ...
Shelby Brown (she/her/hers) is an editor for CNET's services team. She covers tips and tricks for apps, operating systems and devices, as well as mobile gaming and Apple Arcade news. Shelby also ...
23andMe on Tuesday reported that second-quarter revenue fell to $44.1 million from $50 million a year earlier. The ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the ...
The genetics company is closing a unit that was once seen as core to its future.
There are currently no events scheduled on LIVE4. Check back soon to watch live events from across Canada and the world!
Here's what's blowing in the wind in Bay Area business to get your Tuesday morning started: Marqeta, 23andMe, Enphase Energy, ...
Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback